复发难治性血液肿瘤患者CART细胞治疗的护理(2)
[2]Marcus A，Eshhar Z.Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer[J].Expert Opin Biol Ther，2014，14(7)：947-954.
[3]Firor AE，Jares A，Ma Y.From humble beginnings to success in the clinic： Chimeric antigen receptor-modified T-cells and implications for immunotherapy[J].Exp Biol Med (Maywood)，2015，240(8)：1087-1098.
[4]Kochenderfer JN，Feldman SA，Zhao Y，et al.Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor[J].Immunotherapy，2009，32(7)：689-702.
, http://www.100md.com
[5]Porter DL，Levine BL，Kalos M，et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med，2011，365(8)：725-733.
[6]B Till BG，Jensen MC，Wang J，et al.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains： pilot clinical trial results [J].Blood，2012，119(17)：3940-3950.
[7]Grupp SA，Kalos M，Barrett D，et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med，2013，368(16)：1509-1518.
, 百拇医药
[8]Maude SL，Frey N，Shaw PA，et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med，2014，371(16)：1507-1517.
[9]Turtle CJ.Chimeric antigen receptor modified T cell therapy for B cell malignancies [J].Int J Hematol，2014，99(2)：132-140.
[10]Maino E，Scattolin AM，Viero P，et al.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells [J].Mediterr J Hematol Infect Dis，2015，7(1)：2015001.
, 百拇医药
[11]Zhu Y，Tan Y，Ou R，et al.Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies：a systematic review of efficacy and safety in clinical trials [J].Eur J Haematol，2015，6，25.
[12]Dai H，Zhang W，Li X，et al.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia[J].Oncoimmunology，2015，26；4(11)：1027469.
[13]Tasian SK，Gardner RA.CD19-redirected chimeric antigen receptor-modified T cells：a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)[J].Ther Adv Hematol，2015，6(5)：228-241.
[14]Zhang T，Cao L，Xie J，et al.Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials：a meta-analysis[J].Oncotarget，2015，6(32)：33961-33971.
編辑/孙杰, 百拇医药(张萍 戴秀璟 周丽)
[3]Firor AE，Jares A，Ma Y.From humble beginnings to success in the clinic： Chimeric antigen receptor-modified T-cells and implications for immunotherapy[J].Exp Biol Med (Maywood)，2015，240(8)：1087-1098.
[4]Kochenderfer JN，Feldman SA，Zhao Y，et al.Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor[J].Immunotherapy，2009，32(7)：689-702.
, http://www.100md.com
[5]Porter DL，Levine BL，Kalos M，et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med，2011，365(8)：725-733.
[6]B Till BG，Jensen MC，Wang J，et al.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains： pilot clinical trial results [J].Blood，2012，119(17)：3940-3950.
[7]Grupp SA，Kalos M，Barrett D，et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med，2013，368(16)：1509-1518.
, 百拇医药
[8]Maude SL，Frey N，Shaw PA，et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med，2014，371(16)：1507-1517.
[9]Turtle CJ.Chimeric antigen receptor modified T cell therapy for B cell malignancies [J].Int J Hematol，2014，99(2)：132-140.
[10]Maino E，Scattolin AM，Viero P，et al.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells [J].Mediterr J Hematol Infect Dis，2015，7(1)：2015001.
, 百拇医药
[11]Zhu Y，Tan Y，Ou R，et al.Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies：a systematic review of efficacy and safety in clinical trials [J].Eur J Haematol，2015，6，25.
[12]Dai H，Zhang W，Li X，et al.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia[J].Oncoimmunology，2015，26；4(11)：1027469.
[13]Tasian SK，Gardner RA.CD19-redirected chimeric antigen receptor-modified T cells：a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)[J].Ther Adv Hematol，2015，6(5)：228-241.
[14]Zhang T，Cao L，Xie J，et al.Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials：a meta-analysis[J].Oncotarget，2015，6(32)：33961-33971.
編辑/孙杰, 百拇医药(张萍 戴秀璟 周丽)